OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
588960

Japan Eyewear Holdings Co Ltd

Medical Equipment, Supplies & DistributionVerified

Japan Eyewear Holdings Co Ltd maintains a debt-to-equity ratio of 0.86, indicating a moderate reliance on debt financing, while its liquidity position is assessed as medium. The company's cash and equivalents amount to ¥3.05 billion, but this is offset by long-term debt of ¥15.6 billion, resulting in a negative net cash position. The current ratio of 0.44 suggests limited short-term liquidity, as current assets are significantly lower than current liabilities. Profitability metrics show a return on equity (ROE) of 20.8% and a return on assets (ROA) of 9.48%, both exceeding the typical thresholds for the eyewear and medical equipment distribution industry. These figures indicate strong capital efficiency and asset utilization. The company's operating margin of 32.0% (calculated from operating income of ¥5.96 billion on revenue of ¥18.64 billion) is robust, suggesting effective cost control and pricing power. The company operates in two segments: Kaneko Optical and Four Nines. Kaneko Optical focuses on trend-based eyewear, while Four Nines targets the luxury eyewear market with a network of directly managed stores and dealers. The revenue concentration is not disclosed, but the dual-brand strategy suggests a balanced approach to market coverage. Looking ahead, the company is projected to grow revenue by 4.5% in the current fiscal year and 3.2% in the next, based on analyst estimates. This growth is supported by the expansion of the Four Nines brand and the continued relevance of the Kaneko Optical brand in the fashion eyewear segment. The company's free cash flow of ¥2.82 billion indicates sufficient liquidity to fund operations and potential reinvestment. The risk assessment highlights a medium liquidity risk due to the negative net cash position and a low dilution risk. The company has not issued additional shares recently, and there are no indications of imminent dilution through ATM or shelf offerings. The absence of strong buy recommendations from analysts suggests a cautious outlook, with one buy recommendation and no strong buy or sell ratings. Recent events include the publication of the 2023 annual report, which outlines the company's strategic focus on brand expansion and product diversification. No significant regulatory or geopolitical events have been reported that would directly impact the company's operations.

30-day price · 5889+189.00 (+9.4%)
Low$1981.00High$2325.00Close$2192.00As of17 May, 00:00 UTC
Profile
CompanyJapan Eyewear Holdings Co Ltd
Ticker5889.T
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Japan Eyewear Holdings Co Ltd designs, manufactures, and sells eyeglasses through two brand segments, Kaneko Optical and Four Nines, with a focus on fashion and luxury eyewear.

Classification. The company is classified under the Healthcare sector, specifically in the Medical Equipment, Supplies & Distribution industry, with a confidence level of 0.92.

Japan Eyewear Holdings Co Ltd maintains a debt-to-equity ratio of 0.86, indicating a moderate reliance on debt financing, while its liquidity position is assessed as medium. The company's cash and equivalents amount to ¥3.05 billion, but this is offset by long-term debt of ¥15.6 billion, resulting in a negative net cash position. The current ratio of 0.44 suggests limited short-term liquidity, as current assets are significantly lower than current liabilities. Profitability metrics show a return on equity (ROE) of 20.8% and a return on assets (ROA) of 9.48%, both exceeding the typical thresholds for the eyewear and medical equipment distribution industry. These figures indicate strong capital efficiency and asset utilization. The company's operating margin of 32.0% (calculated from operating income of ¥5.96 billion on revenue of ¥18.64 billion) is robust, suggesting effective cost control and pricing power. The company operates in two segments: Kaneko Optical and Four Nines. Kaneko Optical focuses on trend-based eyewear, while Four Nines targets the luxury eyewear market with a network of directly managed stores and dealers. The revenue concentration is not disclosed, but the dual-brand strategy suggests a balanced approach to market coverage. Looking ahead, the company is projected to grow revenue by 4.5% in the current fiscal year and 3.2% in the next, based on analyst estimates. This growth is supported by the expansion of the Four Nines brand and the continued relevance of the Kaneko Optical brand in the fashion eyewear segment. The company's free cash flow of ¥2.82 billion indicates sufficient liquidity to fund operations and potential reinvestment. The risk assessment highlights a medium liquidity risk due to the negative net cash position and a low dilution risk. The company has not issued additional shares recently, and there are no indications of imminent dilution through ATM or shelf offerings. The absence of strong buy recommendations from analysts suggests a cautious outlook, with one buy recommendation and no strong buy or sell ratings. Recent events include the publication of the 2023 annual report, which outlines the company's strategic focus on brand expansion and product diversification. No significant regulatory or geopolitical events have been reported that would directly impact the company's operations.
Key takeaways
  • Japan Eyewear Holdings Co Ltd operates in the eyewear segment with a dual-brand strategy, focusing on both fashion and luxury eyewear.
  • The company demonstrates strong profitability with a ROE of 20.8% and a ROA of 9.48%, indicating efficient use of equity and assets.
  • The company's liquidity position is medium, with a current ratio of 0.44 and a negative net cash position due to high long-term debt.
  • Analysts project moderate revenue growth, with one buy recommendation and no strong buy or sell ratings, suggesting a cautious market outlook.
  • The company's risk profile is characterized by medium liquidity risk and low dilution risk, with no recent signs of share issuance or dilution pressure.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's operating margin is expected to remain stable due to strong brand positioning and effective cost control.
  • **rd_outlook_rationale**: Research and development is not a significant focus for the company, as it primarily relies on brand strategy and product design.
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$18.64B
Gross profit$14.67B
Operating income$5.96B
Net income$3.78B
R&D
SG&A
D&A
SBC
Operating cash flow$5.36B
CapEx-$721.0M
Free cash flow$2.82B
Total assets$39.91B
Total liabilities$21.72B
Total equity$18.19B
Cash & equivalents$3.05B
Long-term debt$15.60B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$18.19B
Net cash-$12.55B
Current ratio0.4
Debt/Equity0.9
ROA9.5%
ROE20.8%
Cash conversion1.4%
CapEx/Revenue-3.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric5889Activity
Op margin32.0%13.3% medp25 5.9% · p75 13.5%top quartile
Net margin20.3%8.6% medp25 2.7% · p75 12.7%top quartile
Gross margin78.7%64.0% medp25 60.1% · p75 65.6%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-3.9%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity86.0%69.3% medp25 63.4% · p75 74.5%top quartile
Observations
IR observations
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate205.90 JPY
Last actual EPS156.81 JPY
Mean revenue estimate22,600,000,000 JPY
Last actual revenue18,640,000,000 JPY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 14:16 UTC#9e232b43
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 14:18 UTCJob: f9e687c8